Preempt future health risks.

Airfinity provides global health intelligence and analytics that decision makers can trust, understand and act upon to save lives.

Cited over 20,000 times in 2021 as a pioneer in predictive intelligence.

the-economist.png
nikkei.png
the-bmj.png
bloomberg.png
cnn.png
nature.png
financial-times.png

Analysis & Insights

Airfinity launches intelligence tool to drive innovation in AMR research
Airfinity launches intelligence tool to drive innovation in AMR research

Airfinity AMR Science360 is a comprehensive tool that tracks and analyses 518 candidates across antibacterial and antifungal therapeutics and vaccines.

Read More →

More from Airfinity
Airfinity expands coverage to include Paroxysmal Nocturnal Haemoglobinuria candidatesCOVID-19 vaccine makers raise prices to off set falling revenue as demand for jabs dropsIntroducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious DiseasesCOVID-19 and flu ‘Twindemic’ could overwhelm hospitals this winterAstraZeneca’s infant RSV drug Beyfortus could generate $1.1bn sales revenue18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workersView All →
In the News
As WTO Considers Patent Waiver on COVID Treatments, Some Say it is Too Late

Health Policy Watch | Nov 24, 2022

Profits drop at BioNTech as vaccine demand wanes

Financial Times | Nov 7, 2022

Will the Biontech vaccine make it to China after all?

WirtschaftsWoche | Nov 2, 2022

COVID-19 and other adult vaccines can drive global disease prevention

The Lancet | Oct 27, 2022

View All →

A pioneer in predictive health intelligence

Understand

What's happening in a given disease area?

Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.

Predict

Identify the true need for a vaccine or a treatment.

Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.

Act

Maximise impact to save lives

Our analytics and probabilistic tools inform key decisions on resource allocation, investment and procurement decisions to maximise impact of a given drug or vaccine and ultimately improve as many lives as possible.

The world's most comprehensive infectious disease solutions.

Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, Monkeypox, Influenza and RSV.

OUR PLATFORM:

New science

Market & Production

Policies

Disease & Prevalence

Learn More →

What our users say?

who

“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”

Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister

hm government

“Airfinity has been instrumental in our country's COVID response.”

Head of UK Government
Vaccine Task Force

ifpma

“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”

Director General,
IFPMA

the economist

“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”

James Fransham, Data Journalist,
The Economist